QQ客服 官方微博 反馈留言

	Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.
	Tan, Fenlai; Gu, Aiqin; Zhang, Yiping; Jiao, Shun Chang; Wang, Chang-Li; He, Jintao; Jia, Xueke; Zhang, Li; Peng, Jiewen; Wu, Meina
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2013
卷号	31期号:15
ISSN号	0732-183X
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3548994
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Tan, Fenlai,Gu, Aiqin,Zhang, Yiping,et al. Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.[J]. JOURNAL OF CLINICAL ONCOLOGY,2013,31(15).
APA	Tan, Fenlai.,Gu, Aiqin.,Zhang, Yiping.,Jiao, Shun Chang.,Wang, Chang-Li.,...&Sun, Yan.(2013).Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study..JOURNAL OF CLINICAL ONCOLOGY,31(15).
MLA	Tan, Fenlai,et al."Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.".JOURNAL OF CLINICAL ONCOLOGY 31.15(2013).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。